Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$56.95 USD
+1.08 (1.93%)
Updated Sep 26, 2024 03:59 PM ET
After-Market: $56.94 -0.01 (-0.02%) 5:40 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Brokerage Reports
Halozyme Therapeutics, Inc. [HALO]
Reports for Purchase
Showing records 141 - 160 ( 205 total )
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:13 Financial Results and Update- Higher-Than- Anticipated Loss on Higher R&D Spend - Eyes On EU Launches - Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Subcutaneous Cinryze Discontinued, Lowering Price Target to $8, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CHMP Positive on SC-HERCEPTIN; Increasing Price Target to $10 per share (from $6) - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Roche Abstracts for GA101 Cause Concern for SC-MabThera Opportunity - Near-Term Risks in SC-HERCEPTIN Decision - Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:13 Financial Results and Update -- Awaiting CHMP sc-HERCEPTIN Decision -- Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Roche Partnership Risks Remain - EU HyQvia Recommendation Offers Little Upside - Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Results and Update - Lowering Fair Value to $6 from $13
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
No Backpedaling from ROCHE on sub cu HERCEPTIN during the US Analyst Presentation -- REITERATE NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL and Removing from Best Ideas List -- ROCHE Downplays subcutaneous HERCEPTIN
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Partnering Progress Validates Technology; Additional Deals Likely in Near-term, Potentially by Year-End 2012 - Reiterate OUTPERFORM and Best Idea
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BEST IDEAS LIST-Best Ideas List -- November 2012 Performance
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of November 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Raising FV to $17 - Analyst Day Takeaways: 2013 Hylenex Insulin Pump Upside and HTI-501 in Cellulite Partnering Opportunities
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ESMO Herceptin Data Supports Current Length of Treatment - Preserves Herceptin SC Opportunity - Reiterate OUTPERFORM and BEST IDEA
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G